Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.FDA approves Teva generic attention deficit hyperactivity disorder therapy
The ANDA is concerned with generic version of Shire’s Adderall XR capsules, which had US sales, including brand and generic sales, of $2bn as of 31 December 2012
The ANDA is concerned with generic version of Shire’s Adderall XR capsules, which had US sales, including brand and generic sales, of $2bn as of 31 December 2012
Under the collaboration, SCiAN will deliver a comprehensive systems and services solution for Web-based data capture and data management, including pharmacovigilance using the SAEPRO module and integrated electronic
According to the firm, the new EMERGE PC/ABS 7700 Advance Resins are PC/ABS blend, which provide a well-balanced, cost-effective solution for powered medical devices offering ignition resistance and
The agreement includes a legal framework for various collaboration projects between the two companies, covering research, development and commercialisation as well as advisory services. The financial terms of
Under the partnership, Covaris’s FS-220 GMP system and Horiba’s LA-950V2 platform will be integrated into a fully automated formulation preparation station with integrated Process Analytical Technology (PAT). The
Remique, manufactured in FDA and GMP certified facilities, is a powder blend of clinically-supported pharmaceutical grade ingredients that can be mixed in water. Able Star founder and president
The longer-acting version of human growth hormone, hGH-CTP, is being developed to treat growth hormone deficiency. PROLOR CEO Dr. Abraham Havron said, "By reducing the dosing frequency to
A violation of the Pharmaceutical Affairs Act coupled with the voluntary recall of ALINAMIN-F5 Injection, Lot H123, was mentioned in the order. Nihon Pharmaceutical, the contract manufacturer and
The collaboration, which is scheduled for two years, will focus on integrating the capabilities and technologies of both the companies to increase the value of specific projects by
According to the strategic collaboration, Mylan gains rights to develop and market Biocon’s Glargine, Lispro and Aspart. Glargine, Lispro and Aspart are the generic equivalents to Sanofi’s Lantus,